Literature DB >> 12135798

Multipin peptide libraries for antibody and receptor epitope screening and characterization.

Gordon Tribbick1.   

Abstract

It has been nearly 15 years since the papers describing the fully systematic epitope mapping approach both for the so-called "continuous" epitopes [Proc. Natl. Acad. Sci. U. S. A. 81 (1984) 3998] and "discontinuous" epitopes [Mol. Immunol. 23 (1986) 709] were published. These seminal papers laid the conceptual foundation for all subsequent developments where a combinatorial approach is applied. Dr. Mario Geysen, the 2000 Kilby Laureate, can certainly lay claim to be the "father of combinatorial chemistry" (http://www.kilby.org/laureates.htm). In this review, I will focus on the aspects of the Multipin technology as they apply to antibody and receptor epitope mapping. Much of what will be presented applies equally well to other applications where peptide libraries (PepSets) and combinatorial approaches are used [Rodda, S.J., 1996. T-cell epitope mapping with synthetic peptides and peripheral blood mononuclear cells. In: Morris, G.E. (Eds.), Methods in Molecular Biology, Vol. 66: Epitope Mapping Protocols. Humana Press, Totowa, NJ, Chap. 30, p. 363; Int. J. Pept. Protein Res. 42 (1993) 384; J. Biol. Chem. 271 (1996) 5603]. Factors and techniques that influence the use of the Multipin method for successful epitope mapping will be presented.

Mesh:

Substances:

Year:  2002        PMID: 12135798     DOI: 10.1016/s0022-1759(02)00138-2

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  13 in total

1.  Antibody mapping of the linear epitopes of CMY-2 and SHV-1 beta-lactamases.

Authors:  Andrea M Hujer; Christopher R Bethel; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 2.  An overview on ELISA techniques for FMD.

Authors:  Li-na Ma; Jie Zhang; Hao-tai Chen; Jian-hua Zhou; Yao-zhong Ding; Yong-sheng Liu
Journal:  Virol J       Date:  2011-09-04       Impact factor: 4.099

3.  Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R.

Authors:  Lydia Aldaz-Carroll; J Charles Whitbeck; Manuel Ponce de Leon; Huan Lou; Lauren Hirao; Stuart N Isaacs; Bernard Moss; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 4.  The use of plants for the production of therapeutic human peptides.

Authors:  Chiara Lico; Luca Santi; Richard M Twyman; Mario Pezzotti; Linda Avesani
Journal:  Plant Cell Rep       Date:  2012-01-05       Impact factor: 4.964

5.  Epitope reactions can be gauged by relative antibody discriminating specificity (RADS) values supported by deletion, substitution and cysteine bridge formation analyses: potential uses in pathogenesis studies.

Authors:  Andrew K I Falconar
Journal:  BMC Res Notes       Date:  2012-07-05

6.  SUPERFICIAL--surface mapping of proteins via structure-based peptide library design.

Authors:  Andrean Goede; Ines S Jaeger; Robert Preissner
Journal:  BMC Bioinformatics       Date:  2005-09-09       Impact factor: 3.169

7.  Fully automated synthesis of (phospho)peptide arrays in microtiter plate wells provides efficient access to protein tyrosine kinase characterization.

Authors:  Carl Saxinger; Thomas P Conrads; David J Goldstein; Timothy D Veenstra
Journal:  BMC Immunol       Date:  2005-01-12       Impact factor: 3.615

Review 8.  Recent Innovations in Peptide Based Targeted Drug Delivery to Cancer Cells.

Authors:  Yosi Gilad; Michael Firer; Gary Gellerman
Journal:  Biomedicines       Date:  2016-05-26

Review 9.  Screening and Optimizing Antimicrobial Peptides by Using SPOT-Synthesis.

Authors:  Paula M López-Pérez; Elizabeth Grimsey; Luc Bourne; Ralf Mikut; Kai Hilpert
Journal:  Front Chem       Date:  2017-04-12       Impact factor: 5.221

Review 10.  The human IgE repertoire.

Authors:  Elisabeth Gadermaier; Mattias Levin; Sabine Flicker; Mats Ohlin
Journal:  Int Arch Allergy Immunol       Date:  2013-11-30       Impact factor: 2.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.